According to relevant data, the value of China's pharmaceutical market will reach 120 billion US dollars in 2020, and it is very likely that the US will become the world's largest pharmaceutical consumer. The strong pharmaceutical market value, coupled with the deepening of the new medical reform and the adjustment of the national macro-policy to the regulation of the pharmaceutical circulation, will make a new round of logistics construction.

The trend of pharmaceutical logistics construction is booming, and the cold chain will become a big winner.

China is the third largest pharmaceutical market in the world. The sustained and stable economic development and the increase in people's demand for pharmaceutical consumption have gradually expanded the scale of the entire pharmaceutical market. The demand for medicines in the market, especially for pharmaceutical cold collections that require cryopreservation, is also increasing year by year. Relevant data show that the sales of pharmaceutical cold products such as vaccine products, injections, tinctures, oral drugs, external medicines, blood products, etc. account for about 10% of the total sales of pharmaceutical circulation enterprises in China. This also promotes pharmaceutical logistics, especially pharmaceutical cold chain logistics, to a certain extent.

In recent years, China's bio-pharmaceutical industry has developed rapidly. China's pharmaceutical companies are often seen on the international stage. Foreign media have also affirmed the progress of China's bio-pharmaceutical technology. Some experts said that the bio-biochemical pharmaceutical industry will continue to grow steadily in the future, and the development of bio-pharmaceutical technology will also become a powerful driving force for the continued expansion of the pharmaceutical cold-chain logistics market.

The problem of drug safety not only affects the hearts of patients and their families, but also attracts the attention of the state. In related cases, the negative events caused by the improper logistics of vaccines, temperature and humidity sensitive drugs have been repeatedly exposed, and the medical cold chain logistics has attracted the attention of government departments and the people. In addition to the above three perspectives, the deepening of the new medical reform and the support of relevant medical policies have also played a icing on the cake to the cold chain logistics.

Although the market prospect of pharmaceutical cold chain logistics is good, industry problems remain to be solved.

Although the market prospect of China's pharmaceutical cold chain logistics is promising, the current status has to be paid attention to by the industry and enterprises.

The first is the question of "quantity" and "quality". In terms of "quantity", China's pharmaceutical cold chain logistics still has a phenomenon of uneven regional development, and the stock of resources is small. According to statistics, in 2017, the number of refrigerated vehicles was 141,000, and that of refrigerated trucks accounted for only 3%. The cold storage still faced an unreasonable resource structure, and there were few cases of less east and west, less cold storage and more cold storage.

In terms of "quality", cold chain equipment is not directly proportional to demand. More importantly, the GSP2012 version of the cold chain standard is from the backward situation to the world's advanced standards. Most of China's cold chain equipment is not well prepared, and it is difficult to make a transition to the world standard. Adding difficulties.

Second is the issue of professionals. Pharmaceutical cold chain logistics has high requirements for talents. It requires not only knowledge of logistics but also medical knowledge. Although there is a large gap in talents in the pharmaceutical logistics industry, at present, most colleges do not have a special medical logistics specialty. The logistics or medical talents recruited by enterprises also need to be cultivated in the future, which requires a lot of cost.

Finally, the issue of industry competition. According to relevant analysis, at present, there are mainly two types of pharmaceutical cold chain logistics, one is traditional pharmaceutical enterprises, and the other is social logistics enterprises. Traditional pharmaceutical companies are mainly concentrated in warehousing management, and the addition of social logistics has intensified competition in the industry. In addition, the State Council's measures for the approval and certification of third-party drug logistics will further push the industry competition to a climax.

Solve industry problems, companies and governments need to work together

In the transportation of medicines, the highest gross profit is cold chain transportation, which has become a market high place for many pharmaceutical logistics companies. However, pharmaceutical cold chain logistics is not an area that any enterprise can cover. It not only has high requirements for the storage and management of medicines, but also has a selection of cold chain equipment and distribution capabilities.

Enterprises should also strengthen the construction of a talent team. Enterprises can cooperate with schools. After all, schools have abundant human resources, which not only saves costs, but also professionally trains relevant talents. In addition, qualified companies can also send excellent employees to study abroad. Advanced foreign technology and experience can provide practical and effective help for employees.

The government should actively introduce relevant laws, regulations and policies to promote the development of pharmaceutical cold chain, and guide the development of pharmaceutical cold chain logistics in the direction of scale, concentration, socialization, standardization and informationization, thus playing a binding and regulating role for the entire industry. Relevant experts also suggested that the government can build a medical traceability system at the public level to protect the development of the pharmaceutical cold chain.

Knee Joint

Total knee replacement is for patients with severe pain and/or severe joint disability due to osteoarthritis, post-traumatic arthritis, rheumatoid arthritis, or previous implant failure.

The total knee joint system consists of femoral condylar , tibial tray,tibial insert and patella.The femoral condylar and tibia tray are made of Co-Cr-Mo in accordance with the quality standards.Tibial insert and patella are made of UHMWPE containing PBHP antioxidants.

The revision knee system is suitable for cemented total knee replacement in patients with severe joint pain or severe disability due to osteoarthritis, post-traumatic arthritis, or rheumatoid arthritis, moderate knee varus, varus, or flexion deformity of the knee, avascular necrosis of the femoral condyle, previous failed knee replacement, osteotomy, or other knee surgery.
Total knee arthroplasty (TKA) is a practical and effective method for the treatment of serious knee arthropathy. However, attention should be paid to the selection of indications, the correction of joint internal and external inversion and flexion deformity, and the correct placement of tibial prosthesis to reduce the loosening of tibial prosthesis. At the same time, early functional exercise should be carried out to reduce postoperative complications. Total knee arthroplasty (TKR) provides an effective treatment for patients with severe knee arthrosis.

knee joint replacement,total knee replacement,knee replacement revision,knee replacement procedure

Jiangsu Aomed Ortho Medical Technology Co.,Ltd , https://www.aomedortho.com